Natera
Tracked across 3 events · 20 articles · First seen Apr 10, 2026 · Last active Aug 05, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Natera is collaborating with Diakonos Oncology Corporation to use its Signatera test in a clinical trial, potentially expanding its market and demonstrating the utility of its precision medicine platform.
May 29, 2026 · 6 articles
Business
Impact: Natera entered a strategic partnership with Aveta Biomics to support the AVTA 30-01 trial, which is expected to increase the use of its Signatera testing platform and potentially boost its revenue and market position. Its shares rose more than 3% in pre-market trading.
Jun 29, 2026 · 7 articles
Regulatory
Impact: Natera is the applicant and primary beneficiary, seeking PMDA approval to expand Signatera's use in Japan. The submission follows recent FDA and NCCN endorsements, reinforcing its leadership in MRD testing.
Aug 05, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Natera live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard